FDA puts hold on ACT trial

The US Food and Drug Administration has put a ‘clinical hold’ on a proposed first-in-man study of a new embryonic stem cell treatment for eye disease, according to the developer.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United States